Journal
BIOCHEMICAL PHARMACOLOGY
Volume 182, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2020.114258
Keywords
N6-methyladenosine; Chemoresistance; Immunotherapy resistance; Targeted therapy resistance; Radioresistance
Categories
Funding
- Natural Science Foundation of Hunan Province, China [2020JJ5934, 2019JJ50932]
- National Natural Science Foundation of China [81703036, 81803035]
- China Postdoctoral Science Foundation [2020 M672521]
Ask authors/readers for more resources
Several strategies, including chemotherapy and radiotherapy, have improved therapeutic outcomes among cancer patients in clinical practice. However, due to their heterogeneity, cancer cells frequently display primary or acquired therapeutic resistance, thereby resulting in treatment failure. The mechanisms underlying cancer therapeutic resistance are complex and varied. Among them, N6-methyladenosine (m6A) RNA modification has gained increasing attention as a potential determinant of therapy resistance within various cancers. In this review, we primarily describe evidence for the effect of the m6A epitranscriptome on RNA homeostasis modulation, which has been shown to alter multiple cellular pathways in cancer research and treatment. Additionally, we discuss the profiles and biological implications of m6A RNA methylation, which is undergoing intensive investigation for its effect on the control of therapeutic resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available